A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension
Information source: Alcon Research
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Open-angle Glaucoma; Ocular Hypertension
Intervention: Travoprost 0.004%/timolol 0.5% ophthalmic solution (Drug); Travoprost ophthalmic solution, 0.004% (Drug); Timolol maleate ophthalmic solution, 0.5% (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Alcon Research Official(s) and/or principal investigator(s):
Theresa Landry, Study Director, Affiliation: Alcon Research
Summary
The purpose of this study is to assess patient compliance with DuoTrav versus concomitant
administration of Timolol 0. 5% plus TRAVATAN in patients with open-angle glaucoma or ocular
hypertension.
Clinical Details
Official title: Compliance Study Comparing DuoTrav to TRAVATAN Plus Timolol Using the Dosing Aid
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Patient compliance
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Adult patients with open-angle glaucoma or ocular hypertension;
- Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
- Visual acuity worse than 0. 60;
- Other protocol-defined exclusion criteria may apply.
Locations and Contacts
Seattle, Seattle, Washington 98104, United States
Additional Information
Starting date: March 2007
Last updated: July 22, 2014
|
